These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37924474)

  • 1. Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity.
    Matias I; Lehmann EW; Zizzari P; Byberg S; Cota D; Torekov SS; Quarta C
    J Endocrinol Invest; 2024 May; 47(5):1289-1294. PubMed ID: 37924474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-Specific Derangement of Circulating Endocannabinoids and
    Forte D; Fanelli F; Mezzullo M; Barone M; Corradi G; Auteri G; Bartoletti D; Martello M; Ottaviani E; Terragna C; Curti A; Pagotto U; Palandri F; Cavo M; Catani L
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
    Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between sex, APOE genotype, endocannabinoids and cognitive change in older adults with metabolic syndrome during a 3-year Mediterranean diet intervention.
    Soldevila-Domenech N; Fagundo B; Cuenca-Royo A; Forcano L; Gomis-González M; Boronat A; Pastor A; Castañer O; Zomeño MD; Goday A; Dierssen M; Baghizadeh Hosseini K; Ros E; Corella D; Martínez-González MÁ; Salas-Salvadó J; Fernández-Aranda F; Fitó M; de la Torre R
    Nutr J; 2024 Jun; 23(1):61. PubMed ID: 38862960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis.
    Caraceni P; Viola A; Piscitelli F; Giannone F; Berzigotti A; Cescon M; Domenicali M; Petrosino S; Giampalma E; Riili A; Grazi G; Golfieri R; Zoli M; Bernardi M; Di Marzo V
    Liver Int; 2010 Jul; 30(6):816-25. PubMed ID: 19840245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.
    Iepsen EW; Lundgren J; Dirksen C; Jensen JE; Pedersen O; Hansen T; Madsbad S; Holst JJ; Torekov SS
    Int J Obes (Lond); 2015 May; 39(5):834-41. PubMed ID: 25287751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry.
    Lam PM; Marczylo TH; Konje JC
    Anal Bioanal Chem; 2010 Nov; 398(5):2089-97. PubMed ID: 20835819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat.
    Castonguay-Paradis S; Lacroix S; Rochefort G; Parent L; Perron J; Martin C; Lamarche B; Raymond F; Flamand N; Di Marzo V; Veilleux A
    Sci Rep; 2020 Sep; 10(1):15975. PubMed ID: 32994521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).
    Hanlon EC
    Psychoneuroendocrinology; 2020 Jan; 111():104471. PubMed ID: 31610409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study.
    Abdulnour J; Yasari S; Rabasa-Lhoret R; Faraj M; Petrosino S; Piscitelli F; Prud' Homme D; Di Marzo V
    Obesity (Silver Spring); 2014 Jan; 22(1):211-6. PubMed ID: 23616305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma endocannabinoid levels in lean, overweight, and obese humans: relationships to intestinal permeability markers, inflammation, and incretin secretion.
    Little TJ; Cvijanovic N; DiPatrizio NV; Argueta DA; Rayner CK; Feinle-Bisset C; Young RL
    Am J Physiol Endocrinol Metab; 2018 Oct; 315(4):E489-E495. PubMed ID: 29438631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity.
    Monteleone AM; Di Marzo V; Monteleone P; Dalle Grave R; Aveta T; Ghoch ME; Piscitelli F; Volpe U; Calugi S; Maj M
    Eur J Nutr; 2016 Jun; 55(4):1799-805. PubMed ID: 26759262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of endocannabinoids and endocannabinoid-like substances in human K3EDTA plasma - LC-MS/MS method validation and pre-analytical characteristics.
    Gurke R; Thomas D; Schreiber Y; Schäfer SMG; Fleck SC; Geisslinger G; Ferreirós N
    Talanta; 2019 Nov; 204():386-394. PubMed ID: 31357310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures.
    Smaga I; Bystrowska B; Gawliński D; Pomierny B; Stankowicz P; Filip M
    Neurotox Res; 2014 Aug; 26(2):190-206. PubMed ID: 24652522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Endocannabinoids in Energy-Balance Regulation in Participants in the Postobese State-a PREVIEW Study.
    Drummen M; Tischmann L; Gatta-Cherifi B; Cota D; Matias I; Raben A; Adam T; Westerterp-Plantenga M
    J Clin Endocrinol Metab; 2020 Jul; 105(7):e2511-20. PubMed ID: 32333763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.
    Le TDV; Fathi P; Watters AB; Ellis BJ; Besing GK; Bozadjieva-Kramer N; Perez MB; Sullivan AI; Rose JP; Baggio LL; Koehler J; Brown JL; Bales MB; Nwaba KG; Campbell JE; Drucker DJ; Potthoff MJ; Seeley RJ; Ayala JE
    Mol Metab; 2023 Jun; 72():101718. PubMed ID: 37030441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
    Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
    Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
    Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
    BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells.
    Matias I; Gonthier MP; Petrosino S; Docimo L; Capasso R; Hoareau L; Monteleone P; Roche R; Izzo AA; Di Marzo V
    Br J Pharmacol; 2007 Nov; 152(5):676-90. PubMed ID: 17704823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.